Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store.
Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777.
A link to the prescribing information can be found in the header.
Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex) is indicated in adults for symptomatic treatment of spasmodic torticollis
Please click here to see the full therapeutic indications.
CLIMB Online
Cervical Dystonia
Dysport® Dosing Map for Cervical Dystonia
A reference guide to the dosing of Dysport® for the symptomatic treatment of cervical dystonia.
DYS-UK-008781
Dysport® Reconstitution Guide
7 minutes
How to prepare, reconstitute and store Dysport®
DYS-UK-008719
Cervical Dystonia Disease Background – eLearning Module
20 minutes
An overview of clinical characteristics of cervical dystonia, the sub-types of CD, and the impact CD can have on patients
DYS-UK-008759
Cervical Dystonia Diagnosis – eLearning Module
20 minutes
An overview of the clinical history of CD in adults, the methods of diagnosing cervical dystonia, and the clinical examination required for patients suspected of having CD
DYS-UK-008753
Dysport® Clinical Studies in Cervical Dystonia – eLearning Module
20 minutes
An overview of the phase 3 clinical studies of Dysport® in cervical dystonia
DYS-UK-008758
Tackling the capacity challenge in your clinics with Dysport®
7 minutes
Dr Jonathan Evans discusses Dysport® time to retreatment in clinical trials and how moving to Dysport® may allow adult patients with cervical dystonia to avoid unnecessary appointments and contribute to increasing clinic capacity
DYS-UK-008738
Navigating the Switch between BoNT-As: The North Staffordshire Rehabilitation Centre Experience
10 minutes
Dr Clive Bezzina shares his personal experience switching between BoNT-As within his spasticity service, and the outcomes seen for both the patients and the service.
DYS-UK-008724
Flexibility with Dysport in Clinical Practice: A case study (36F with CD)
5 minutes
Presented by: Dr Tim Harrower
DYS-UK-008720
Making sense of the changing NHS and funding flows
12 minutes
Dr Judy Willits discusses how the NHS payment scheme has evolved and what the changes could mean for your botulinum toxin services.
DYS-UK-008730
Patient case study – 51-year-old female with CD
13 minutes
Includes footage of the clinical assessment and injection procedure
Presented by: Dr Anna Castagna
DYS-UK-008469
Patient case study – 60-year-old female with CD
13 minutes
Includes footage of the clinical assessment and injection procedure
Presented by: Dr Anna Castagna
DYS-UK-008470
BoNT Immunogenicity: The difference between neutralising and non-neutralising antibodies
3 minutes
Understand the difference between neutralising and non-neutralising antibodies and how this difference should be considered during clinical decision-making.
DYS-UK-008783
Demystifying the Clinical Relevance of BoNT Immunogenicity
5 minutes
Learn about the difference between neutralising and non-neutralising antibodies, and factors to consider when investigating non-response to BoNT treatment
Presented by: Dr Tim Harrower
DYS-UK-008723
Advanced concepts in diagnosis and therapy of cervical dystonia: The Col-Cap-Concept
34 minutes
Presented by: Prof W. Jost
DYS-UK-008471
Life between Botulinum Neurotoxin Type A (BoNT-A) injections: The gap for patients living with Cervical Dystonia
34 minutes
Presented by: Dr Timothy Harrower
DYS-UK-008474
Dysport® Mechanism of Action
3 minutes
DYS-UK-008722
© IPSEN Ltd, 5th Floor The Point, 37 North Wharf Road, London, W2 1AF, United Kingdom. All rights reserved. August 2024 DYS-UK-008823
